These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 18778390)

  • 1. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
    Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
    Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
    Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
    Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
    Spire B; Lucas GM; Carrieri MP
    Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.
    Lawrinson P; Ali R; Buavirat A; Chiamwongpaet S; Dvoryak S; Habrat B; Jie S; Mardiati R; Mokri A; Moskalewicz J; Newcombe D; Poznyak V; Subata E; Uchtenhagen A; Utami DS; Vial R; Zhao C
    Addiction; 2008 Sep; 103(9):1484-92. PubMed ID: 18636999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.
    Raffa JD; Grebely J; Tossonian H; Wong T; Viljoen M; Khara M; Mead A; McLean M; Duncan F; Petkau AJ; DeVlaming S; Conway B
    Drug Alcohol Depend; 2007 Jul; 89(2-3):306-9. PubMed ID: 17383117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
    Schaub M; Chtenguelov V; Subata E; Weiler G; Uchtenhagen A
    Int J Drug Policy; 2010 May; 21(3):229-33. PubMed ID: 19926271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
    Protopopescu C; Raffi F; Roux P; Reynes J; Dellamonica P; Spire B; Leport C; Carrieri MP;
    J Antimicrob Chemother; 2009 Sep; 64(3):599-606. PubMed ID: 19602563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).
    Carrieri MP; Villes V; Raffi F; Protopopescu C; Preau M; Salmon D; Taieb A; Lang JM; Verdon R; Chene G; Spire B;
    Int J Drug Policy; 2007 Aug; 18(4):288-95. PubMed ID: 17689377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.
    Roux P; Villes V; Blanche J; Bry D; Spire B; Feroni I; Carrieri MP
    Drug Alcohol Depend; 2008 Sep; 97(1-2):105-13. PubMed ID: 18479840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
    Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
    Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
    Smit C; Lindenburg K; Geskus RB; Brinkman K; Coutinho RA; Prins M
    Addiction; 2006 Mar; 101(3):433-40. PubMed ID: 16499516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health related quality of life among both current and former injection drug users who are HIV-infected.
    Préau M; Protopopescu C; Spire B; Sobel A; Dellamonica P; Moatti JP; Carrieri MP;
    Drug Alcohol Depend; 2007 Jan; 86(2-3):175-82. PubMed ID: 16930864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of short-term success of antiretroviral therapy in HIV infection.
    Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
    J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.